In summary, these results further support the hypothesis that IFNγ signaling can promote RMC tumor cell state changes, prompting further investigation into the pharmacological inhibition of myeloid-affiliated mediator, p300, which is downstream of IFNGR1. This evidence concerns the gene IFNG and neoplasm.